The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine

European Journal of Heart Failure

Volumn 7, Issue 5, 2005, Pages 882-887

  Avgeropoulou, Catherine ^a   Andreadou, Ioanna ^b   Markantonis Kyroudis, Sophia ^b   Demopoulou, Maritina ^b   Missovoulos, Platon ^a   Androulakis, Aris ^a   Kallikazaros, Ioannis ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

BNP; Dobutamine; Heart failure; Levosimendan; Oxidative damage; Pro inflammatory cytokines

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM SENSITIZER; DOBUTAMINE; INTERLEUKIN 6; LEVOSIMENDAN; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN; INFLAMMATION; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; DOBUTAMINE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PYRIDAZINES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23744462187     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.02.002     Document Type: Article

References (37)

1. V.M. Conraads, J.M. Bosmans, and C.J. Vrints Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia Int J Cardiol 85 2002 33 49
2. M. Yoshimura, H. Yasue, and K. Okumura Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure Circulation 87 1993 464 469
3. M. Mukoyama, K. Nakao, and K. Hosoda Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide J Clin Invest 87 1991 1402 1412
4. B.C. Stein, and R.I. Levin Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease Am Heart J 135 1998 914 923
5. G.A. Sagnella Measurement and importance of plasma brain natriuretic peptide and related peptides Ann Clin Biochem 38 2001 83 93
6. K. Maeda, T. Tsutamoto, and A. Wada High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J Am Coll Cardiol 36 2000 1587 1593
7. R.W. Troughton, C.M. Frampton, and T.G. Yandle Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
8. S. Adamopoulos, J. Parissis, and D. Kremastinos A glossary of circulating cytokines in chronic heart failure Eur J Heart Fail 3 5 2001 517 526
9. A.M. Feldman, A. Combes, and D. Wagner The role of tumor necrosis factor in the pathophysiology of heart failure J Am Coll Cardiol 35 2000 537 544
10. B. Levine, J. Kalman, and L. Mayer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 323 1990 236 241
11. M. Testa, M. Yeh, and P. Lee Circulating levels of cytokines and their endogenous mediators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension J Am Coll Cardiol 28 1996 964 971
12. G. Torre-Amione, S. Kapadia, and C. Benedict Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD) J Am Coll Cardiol 27 1996 1201 1206
13. G. Plenz, Z.F. Song, and T.D.T. Tjan Activation of the cardiac interleukin-6 system in advanced heart failure Eur J Heart Fail 3 2001 415 421
14. T. Tsutamoto, T. Hisanaga, and A. Wada Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure J Am Coll Cardiol 31 1998 391 398
15. M.C. Polidori, K. Savino, and G. Alunni Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity Free Radic Biol Med 32 2002 148 152
16. 2+-sensitization Eur J Pharmacol 486 2004 1 8
17. T. Sorsa, S. Heikkinen, and M.B. Abbott Binding of levosimendan, a calcium sensitizer, to cardiac troponin C J Biol Chem 276 2001 9337 9343
18. F. Follath, J.G.F. Cleland, and H. Just Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double blind trial Lancet 360 2002 196 202
19. I. Andreadou, A. Tasouli, and E. Iliodromitis Reduction of myocardial infarct size in rabbits by a novel indole derivative with antioxidant and free radical scavenging properties Eur J Pharmacol 453 2002 271 277
20. I. Andreadou, E. Iliodromitis, E. Mikros, E. Bofilis, A. Zoga, and M. Constantinou Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress Free Radic Biol Med 37 2004 500 510
21. B.A. Groenning, J.C. Nilsson, and L. Sondergaard Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations Eur J Heart Fail 3 2001 699 708
22. A. Kjaer, and B. Hesse Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives Clin Physiol 6 2001 661 672
23. R. Latini, S. Masson, and I. Anand The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-heFT Eur Heart J 25 2004 292 299
24. A.M. Richards, R. Doughty, and M.G. Nicholls Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction Circulation 99 1999 786 792
25. D.R. Murdoch, T.A. McDonagh, and J. Byrne Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy Am Heart J 138 1999 1126 1132.
26. A.S. Maisel Use of BNP levels in monitoring hospitalized heart failure patients with heart failure Heart Fail Rev 8 2003 339 344
27. V.S. Moiseyev, P. Põder, and N. Andrejevs Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction Eur Heart J 23 2002 1422 1432
28. E.R. Mohler, L.C. Sorensen, and J.K. Ghali Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial J Am Coll Cardiol 30 1997 35 41
29. K.M. Mohler, D.S. Torrance, and C.A. Smiht Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1993 1548 1561
30. A. Deswal, N.J. Petersen, and A.M. Feldman Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from the Vesnarinone Trial (VEST) Circulation 103 2001 2055 2059
31. J.T. Parissis, S. Adamopoulos, and C. Antoniades Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure Am J Cardiol 93 2004 1309 1312
32. D.J. Grieve, and A.J. Shah Oxidative stress in heart failure: more than just damage Eur Heart J 24 2003 2161 2163
33. A.L. Farre, and S. Casado Heart failure, redox alterations and endothelial dysfunction Hypertension 38 2001 1400 1405
34. M. Keith, A. Geranmayegan, and M.J. Sole Increased oxidative stress in patients with congestive heart failure J Am Coll Cardiol 31 1998 1352 1356
35. M. Kivikko, S. Antila, and J. Eha Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure J Clin Pharmacol 42 2002 43 51
36. M. Kivikko, L. Lehtonen, and W.S Colucci Sustained hemodynamic effects of intravenous levosimendan Circulation 107 2003 81 86
37. M.N. Zairis, C. Apostolatos, P. Anastasiadis, D. Mytas, C. Katsaris, and N. Kouris The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure study (CASINO) J Am Coll Cardiol 43 2004 A206 A207 [Abstract]